Subsequent Entry Biologics in Canada: Current State of the Science
The Canadian Society for Pharmaceutical Sciences organized a workshop on the current state of sciences of subsequent entry biologics (SEBs, biosimilars) on December 10th 2014 in the Health Canada location in Ottawa, ON. The day-long workshop provided an opportunity to discuss recent regulatory devel...
Saved in:
Main Authors: | Laszlo Endrenyi (Author), Fakhreddin Jamali (Author), Raimar Loebenberg (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2015-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information
by: Catherine Lau, et al.
Published: (2022) -
Biowaiver for Immediate and Modified Release Dosage forms Scientific summary of the CSPS workshop
by: Raimar Loebenberg
Published: (2020) -
The Impact of Tiered-Pricing Framework on Generic Entry in Canada
by: Wei Zhang, et al.
Published: (2022) -
Improved Sensitive High Performance Liquid Chromatography Assay for Glucosamine in Human and Rat Biological Samples with Fluorescence Detection
by: Fakhreddin Jamali, et al.
Published: (2010) -
Determination of Bioequivalence for Drugs with Narrow Therapeutic Index: Reduction of the Regulatory Burden
by: Laszlo Endrenyi, et al.
Published: (2013)